𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis

✍ Scribed by Shinichiro Tada; Hirotoshi Ebinuma; Hidetsugu Saito; Toshifumi Hibi

Publisher
Springer Japan
Year
2006
Tongue
English
Weight
148 KB
Volume
41
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prevalence and predictors of esophageal
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis
✍ Claudia O. Zein; Keith D. Lindor; Paul Angulo πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 2 views

Patients with primary sclerosing cholangitis (PSC) may develop and bleed from esophageal varices. However, the exact prevalence of esophageal varices in patients with PSC remains unknown and potential predictors of esophageal varices in this population have not been identified. Our aim was to determ

Advances in the diagnosis of cholangioca
Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis
✍ Laura E. Moreno Luna; Gregory J. Gores πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 1 views

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic liver disease characterized by inflammatory destruction of the biliary tree. It slowly progresses, resulting in biliary fibrosis and obliteration leading to end-stage liver disease. The most feared complication of PSC is the d

Long-term results of patients undergoing
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis
✍ Ivo W. Graziadei; Russell H. Wiesner; Paul J. Marotta; Michael K. Porayko; J. Ei πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 102 KB πŸ‘ 2 views

Liver transplantation is the only effective therapeutic option for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC). In this study, we analyzed a single center's experience with 150 consecutive PSC patients who received 174 liver allografts. Mean follow-up was 55 mon